NCT00578435View on ClinicalTrials.gov

Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 1994

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Genetic DisordersSickle Cell Anemia
Interventions
PROCEDURE

Busulfan, Cyclophosphamide, BMD

Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00578435 - Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis | Biotech Hunter | Biotech Hunter